Allena Pharmaceuticals (NASDAQ:ALNA) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.
A number of other research firms have also recently commented on ALNA. Wedbush began coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $30.00 target price for the company. Cowen began coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Jefferies Group began coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Credit Suisse Group began coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Allena Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $24.67.
Shares of Allena Pharmaceuticals (NASDAQ ALNA) opened at $8.23 on Friday. Allena Pharmaceuticals has a 1 year low of $8.14 and a 1 year high of $15.40. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of -0.09.
In other news, Director James N. Topper bought 500,000 shares of the stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of the stock in a transaction dated Monday, November 6th. The stock was purchased at an average price of $14.00 per share, with a total value of $504,000.00. The disclosure for this purchase can be found here.
An institutional investor recently bought a new position in Allena Pharmaceuticals stock. Dean Capital Investments Management LLC acquired a new stake in shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,568 shares of the company’s stock, valued at approximately $116,000. Dean Capital Investments Management LLC owned about 0.06% of Allena Pharmaceuticals at the end of the most recent quarter. 0.01% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/02/allena-pharmaceuticals-alna-upgraded-at-valuengine.html.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.